Therapeutic approaches for T790M mutation positive non-small-cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Therapeutic approaches for T790M mutation positive non-small-cell lung cancer

Published:2018-08-14 Issue:10 Volume:18 Page:1021-1030
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Attili Ilaria¹,Karachaliou Niki²³,Conte PierFranco¹,Bonanno Laura⁴,Rosell Rafael³⁵⁶⁷

Affiliation:

1. Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Padova, Italy

2. Instituto Oncológico Dr Rosell (IOR), University Hospital Sagrat Cor, Barcelona, Spain

3. Coyote Research Group, Pangaea Oncology, Laboratory of Molecular Biology, Quirón-Dexeus University Institute, Barcelona, Spain

4. Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padova, Italy

5. Institut d’Investigació en Ciències Germans Trias i Pujol, Badalona, Spain

6. Instituto Oncológico Dr Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain

7. Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain

Funder

La Caixa Foundation, Barcelona

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2018.1508347

Reference126 articles.

1. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

2. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

3. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

4. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

5. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development;Cancer Treatment Reviews;2024-09

2. An ultrasensitive DNA-enhanced amplification method for detecting cfDNA drug-resistant mutations in non-small cell lung cancer with selective FEN-assisted degradation of dominant somatic fragments;Clinical Chemistry and Laboratory Medicine (CCLM);2024-08-01

3. Post-Progression Analysis of EGFR-Mutant NSCLC Following Osimertinib Therapy in Real-World Settings;Cancers;2024-07-19

4. New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations;Cancers;2023-10-20

5. The Impact of Liquid Biopsies Positive for EGFR Mutations on Overall Survival in Non-Small Cell Lung Cancer Patients;Diagnostics;2023-07-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3